MELADIAG: A panel of DNA biomarkers dedicated to melanoma diagnosis.

Benfodda, M.; Marinho, E.; Kumar, Rajiv; Lamoril, J.; Â©ocreux, Marion Rã; Beaudoux, Olivia; Grange, Florent; Dechamps, Lydia; Bensussan, Armand; Merrouche, Yacine; Soufir, Nadem

doi:10.1200/jco.2016.34.15_suppl.e23258

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We had transition percentages (46.82%) at the malignant tumour levels that are higher compared to benign (21.18%) and control (26.51%) tumors. Our results are in line with those of [18] working on the diagnosis of melanoma. The sequencing of BRAF showed the presence of very many mutations and 80% of the mutations were C > Transitions.…”

Section: Discussionsupporting

confidence: 91%

Genetic Diversity and Structuring of the BRAF gene in Breast Tumors

2019

European Journal of Medical Research and Clinical Trials

View full text Add to dashboard Cite

The International Agency for Research on Cancer (IARC) estimates an increase in breast cancer worldwide. In Senegal, the most common malignant tumour in women is breast cancer. But also in Senegal as in most African countries, benign tumours occupy an important place in mammary pathologies. To better understand the impact of nucleotide variability and genetic instability of benign and malignant breast tumours, we used the BRAF gene, which is a nuclear gene.This work allowed us to compare the polymorphism, diversity, structure and genetic evolution of exon 15 of the BRAF gene between patients with benign tumours, malignant breast tumours and control subjects. The analysis at the identification of mutation of exon 15 of the BRAF gene led us to conclude that BRAF was mutated in (1.5%) of cases. We observed a synonymous mutation A598A in malignant tumours. Our results showed that somatic mutations of this BRAF gene were common in Senegalese patients with both benign and malignant breast tumours. So our results allowed us to conclude that the BRAF gene is involved in breast tumours.

show abstract

Section: Discussionsupporting

confidence: 91%

Genetic Diversity and Structuring of the BRAF gene in Breast Tumors

2019

European Journal of Medical Research and Clinical Trials

View full text Add to dashboard Cite

show abstract

MELADIAG: A panel of DNA biomarkers dedicated to melanoma diagnosis.

Cited by 1 publication

References 0 publications

Genetic Diversity and Structuring of the BRAF gene in Breast Tumors

Genetic Diversity and Structuring of the BRAF gene in Breast Tumors

Contact Info

Product

Resources

About